Provided by Tiger Trade Technology Pte. Ltd.

Contineum Therapeutics, INC.

17.19
+1.177.30%
Post-market: 17.190.00000.00%19:30 EDT
Volume:353.91K
Turnover:6.02M
Market Cap:646.71M
PE:-9.99
High:17.35
Open:16.18
Low:15.88
Close:16.02
52wk High:17.35
52wk Low:8.60
Shares:37.62M
Float Shares:27.82M
Volume Ratio:0.42
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7201
EPS(LYR):-2.1700
ROE:-28.01%
ROA:-19.15%
PB:2.70
PE(LYR):-7.92

Loading ...

Contineum CSO Daniel S. Lorrain disposes of 4,170 shares for $56,025

Reuters
·
Apr 07

Contineum Therapeutics grants 51,000-share inducement stock option under 2026 employment plan

Reuters
·
Mar 14

Contineum Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
Mar 06

RBC Capital Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM)

TIPRANKS
·
Mar 06

Stifel Nicolaus Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)

TIPRANKS
·
Mar 06

Contineum Therapeutics Inc - May Offer Class a Common Stock up to $100 Mln Through Leerink Partners - SEC Filing

THOMSON REUTERS
·
Mar 06

Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress

TIPRANKS
·
Mar 06

Contineum Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 06

Contineum Therapeutics Q4 EPS $(0.49) Beats $(0.59) Estimate

Benzinga Earnings
·
Mar 06

Contineum Q4 FY2025 net loss totals USD 15.2 million as G&A expenses rise 8.0% to USD 4.4 million

Reuters
·
Mar 06

Contineum Therapeutics Inc: Qtrly EPS $-0.49

THOMSON REUTERS
·
Mar 06

Press Release: Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Dow Jones
·
Mar 06

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 05

Contineum Therapeutics to Present at Leerink Partners Global Healthcare Conference

Reuters
·
Mar 04

Contineum Therapeutics CSO Daniel S. Lorrain Disposes of Common Shares

Reuters
·
Mar 03

Contineum Therapeutics CMO and Head of Development Tim Watkins Disposes of Common Shares

Reuters
·
Mar 03

Contineum Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview

Reuters
·
Mar 03

Contineum Therapeutics CEO and President Carmine N. Stengone Disposes of Common Shares

Reuters
·
Feb 27

Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Disposes of Common Shares

Reuters
·
Feb 27

Contineum Therapeutics CSO Daniel S. Lorrain Disposes of Common Shares

Reuters
·
Feb 21